Total | Primary infection | Secondary infection | |||
---|---|---|---|---|---|
Plasma | ELISA | All samples | 66 % (159/241) | 95.7 % (66/69) | 51.1 % (69/135) |
DAOF ≤ 3 | 94.4 % (67/71) | 100 % (29/29) | 88.6 % (31/35) | ||
DAOF 4–7 | 66.7 % (82/123) | 93.9 % (31/33) | 51.4 % (36/70) | ||
DAOF 8–12 | 21.3 % (10/47) | 85.7 % (6/7) | 6.7 % (2/30) | ||
Urine | ELISA | All samples | 14.3 % (63/440) | 18.3 % (23/126) | 8.1 % (20/246) |
DAOF ≤ 3 | 9.9 % (8/81) | 15.6 % (5/32) | 2.4 % (1/41) | ||
DAOF 4–7 | 19.2 % (52/271) | 21.5 % (17/79) | 12.3 % (19/154) | ||
DAOF 8–12 | 3.4 % (3/88) | 6.7 % (1/15) | 0 % (0/51) | ||
Urine | RDT | All samples | 15.5 % (68/440) | 18.3 % (23/126) | 10.6 % (26/246) |
DAOF ≤ 3 | 11.1 % (9/81) | 15.6 % (5/32) | 4.9 % (2/41) | ||
DAOF 4–7 | 21 % (57/271) | 21.5 % (17/79) | 15.6 % (24/154) | ||
DAOF 8–12 | 2.3 % (2/88) | 6.7 % (1/15) | 0 % (0/51) | ||
Saliva | ELISA | All samples | 24.7 % (72/291) | 43.5 % (37/85) | 15.5 % (27/174) |
DAOF ≤ 3 | 25.5 % (12/47) | 41.2 % (7/17) | 19.2 % (5/26) | ||
DAOF 4–7 | 29.9 % (55/184) | 46.7 % (28/60) | 19.4 % (21/108) | ||
DAOF 8–12 | 8.3 % (5/60) | 25 % (2/8) | 2.5 % (1/40) | ||
Saliva | RDT | All samples | 20.8 % (60/289) b | 31 % (26/84) a | 16.2 % (28/173) a |
DAOF ≤ 3 | 14.9 % (7/47) | 23.5 % (4/17) | 11.5 % (3/26) | ||
DAOF 4–7 | 25.7 % (47/183) a | 33.9 % (20/59) a | 19.4 % (21/108) a | ||
DAOF 8–12 | 10.2 % (6/59) a | 25 % (2/8) | 10.3 % (4/39) a |